Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Keep an eye on important metrics and work closely with your healthcare team to tackle any challenges early
GLP-1 medications have been disruptive because of the dramatic impact on weight loss, but the drugs are just another headwind that manufacturers and retailers need to navigate through to ensure they are delivering on the needs of their target consumers. Perhaps unsurprisingly, leaders at CPGs including Hershey, Coca-Cola, Mondelez, PepsiCo, and Keurig Dr Pepper were consistently queried during the most recent round of earnings calls to share their perspectives on potential consumer behavior impacts
It's important to note that Wegovy (semaglutide 2.4 mg) and Saxenda (liraglutide 3 mg) are licensed for weight management in the UK, while Ozempic (semaglutide) is only licensed for type 2 diabetes treatment, not for weight management
This is important because the bodys toxic load and toxin clearance capability are reduced
A 2025 RAND survey on GLP-1 use in the United States found that about half of adults on GLP-1 agonists report experiencing nausea
US$ 21.71
US$ 27.22
US$ 29.28
US$ 26.00
US$ 25.25
